Abstract 3479
Background
The prognostic value of proliferative and apoptotic activity of tumors in patients with osteogenic sarcoma was investigated in order to determine which genes are involved in their pathogenesis and prognosis.
Methods
Immunohistochemical methods (IHC) were used to study the expression of p53, bcl-2, Ki-67 in patients with osteogenic sarcoma in comparison with the effectiveness of treatment. Patients with positive results of chemotherapy (group 1) underwent radiotherapy for a radical program in the total focal dose up to 60-70 Gy. When receiving a good effect from radiation therapy (group 2), patients received another 4-5 courses of chemotherapy. Surgical treatment was performed in 36 patients (41.9%) with a large pulpy component of the tumor and with ineffective chemotherapy or chemoradiotherapy (group 3).
Results
In group 1 patients, who received chemotherapy, the full effect was observed only in patients with negative and weakly positive IHC reactions to the p53 (18%), Ki-67 (16%) and bcl-2 (10%). For partial effect, the phenotype of tumor cells was as follows: negative and weakly positive IHC reaction to the mutant p53 gene was seen in 52% of patients, in Ki-67 - in 62%, and bcl-2 - in 48%. In 6% of patients in this group, the effect of therapy was negative. In the second group, only 10% of the patients had a full effect of the therapy, while in all patients, the tumor cells were mutant p53 negative, 5% had average Ki-67 and bcl2, and 5% were Ki-67 and bcl-2 negative. 25% of patients in this group had partial effects. In 20% of patients in this group, absence or weak expression of mutant p53 gene was detected in tumor cells, expression of Ki67 and bcl 2 genes in 15% was average, the remaining patients were with Ki-67 and bcl-2 negative. In group 3, 56% of patients had positive effect with therapy, among them, those with weak or no, expression of mutant gene p53 were 75% and only 12.5% showed moderate expression of this protein.
Conclusions
Our findings suggest that the study of the expression of the mutated p53 suppressor gene is a more informative prognostic factor in osteogenic sarcoma and contributes to an understanding of the mechanisms of cancer, development of new diagnostic methods and pathogenetically valid approaches to the therapy of osteogenic sarcoma.
Clinical trial identification
Legal entity responsible for the study
Ministry of Health of Republic of Uzbekistan.
Funding
Has not received any funding.
Editorial Acknowledgement
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2595 - Real-Life Utilization of Genomic testing for invasive Breast Cancer patients in Italy and France reduces Chemotherapy Recommendations
Presenter: Sandro Barni
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2343 - Benefit of adjuvant chemotherapy in hormone receptor-positive, HER2-negative, invasive lobular carcinoma of the breast
Presenter: Alexandre De Nonneville
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2990 - Baseline lymphocyte counts predict distant recurrence in early breast cancer
Presenter: Gun Min Kim
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4532 - A propensity score analysis exploring the impact of the addition of adjuvant chemotherapy (aCT) to hormone therapy (aHT) in a multi-center series of resected luminal early stage pure Invasive Lobular Breast Carcinoma (ILC).
Presenter: Luisa Carbognin
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2344 - Benefit of Adjuvant Systemic Therapies in HR+ HER2- pT1ab Node-Negative Breast Carcinomas
Presenter: Alexandre De Nonneville
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3525 - Anti-proliferative effect of oral metronomic vinorelbine in PAM50 Luminal/HER2-negative early breast cancer (SOLTI-1501 VENTANA): an open-label, randomized, three-arm, multicenter, window-of-opportunity study
Presenter: Aleix Prat
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3908 - Clinicopathologic significance of androgen receptor expression and discordant receptor status during progression in breast cancer
Presenter: Chan Heun Park
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4075 - The outcomes of early breast cancers utilizing the Oncotype Dx Recurrence score (RS) instead of Clinico-pathological (CP) factors for prognostic risk assessment: A Single Institution Experience
Presenter: Adhar Alsayed
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
738 - Circulating tumor cells as a prognostic marker in non metastatic breast cancer patients.
Presenter: Summar Elmorshidy
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3151 - Molecular subtyping of breast cancer by dedicated breast PET
Presenter: Satoshi Sueoka
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract